Spruce Biosciences Inc (SPRB)
Spruce Biosciences, Inc. is a biopharmaceutical company developing therapies for neurological disorders and other serious rare diseases. Its pipeline includes TA-ERT, an enzyme replacement therapy candidate for Sanfilippo Syndrome Type B, as well as Tildacerfont, which is being studied for a severe mental disorder marked by depressed mood and related cognitive, emotional, and physical symptoms. The company is also advancing SPR202 for Congenital Adrenal Hyperplasia, a chronic rare disease with no cure. Spruce Biosciences has a license agreement with Eli Lilly and Company covering research, development, and commercialization of certain pharmaceutical compounds, and a collaboration with Kaken Pharmaceutical Co. Ltd. focused on Tildacerfont for CAH in Japan. Incorporated in 2014, the company is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SPRB
|
$42.52
|
-6.0% Downside
|
Fair
|
$151
|
233.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-3.4x
|
3.6x
|
—
|
122.5 M
|
78.188 M
|
5.5%
|
96.4%
|
-4.7
|
—
|
78.9%
|
